Holoprosencephaly-diencephalic hamartoblastoma (HDH).

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home Genes Leukemias Solid Tumors Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Holoprosencephaly-diencephalic hamartoblastoma (HDH).

Written	2007-09	Marco Castori, Paola Grammatico
		Medical Genetics, Institute of Experimental Medicine, Università La Sapienza, San Camillo-Forlanini Hospital, Rome, Italy

(Note : for Links provided by Atlas : click)

Identity

Other names Holoprosencephaly-diencephalic hamartoblastoma association, Holoprosencephaly-hypothalamic hamartoblastoma, Holoprosencephaly-diencephalic hamartoma
Atlas_Id 10142

Genes implicated in SHH SOX2
Note HDH is an extremely rare developmental field defect primarily involving the prosencephalon. The most accredited hypothesis is that the hypothalamic hamartoma formation, which occurs early in embryogenesis, produces a cascading process of subsequent craniofacial defects including holoprosencephaly, microphthalmia, hemifacial microsomia, neuronal migration defects, and brainstem/posterior fossa and meningeal anomalies.

Inheritance The inheritance pattern of HDH is still obscure and probably heterogeneous. Environmental/stochastic causes may also contribute for a significant proportion of cases.

Clinics

Phenotype and clinics HDH equally affects males and females. Nearly 100% of the patients present some features of holoprosencephaly. The spectrum of these anomalies is wide, ranging from alobar holoprosencephaly to microforms, such as isolated single central medial incisive, or cleft palate. The most consistent holoprosencephalic features are hypo/aplasia of the corpus callosum, arhinencephaly and premaxillary agenesis. Unilateral or bilateral microphathalmia and neuronal migration/cortical anomalies are quite common abnormalities. Additional findings include meningeal abnormalities, such as cysts and dysplasia, and brainstem and posterior fossa malformations. The first and second branchial arches derivatives may also be asymmetrically affected leading to a significant clinical overlap with the oculo-auriculo-vertebral spectrum. Fifty to sixty per cent of the patients also show extracephalic features, with an excess of midline and laterality determination abnormalities, thus configuring a polytopic developmental field defect. The axial skeleton is the most commonly involved structure, while heart, kidneys, gastrointestinal tract, genitourinary system and limbs are more rarely affected.

Neoplastic risk On embryological perspective, hypothalamic hamartoma/hamartoblastoma is a malformation, not a true tumor. Other benign growth lesions, including meningeal angiomatosis, frontal lipoma, tongue cyst, epignathus and gum nodules, have been observed in about 20% of the cases. However, no increased risk of malignancies has been reported in HDH patients.

Treatment In those patients who survive (see below), the treatment is usually conservative and symptomatic. Surgical repair could be requested for specific potentially life-treating or disfiguring malformations, such as cleft palate, congenital heart disease and genital anomalies. Invasive treatment of hypothalamic hamartomas is usually requested only in presence of intractable seizures. In this case, the experience is limited to non syndromic hamartomas and therapeutic options include surgical resection by conventional craniotomy, microsurgical technique via transcallosal approach and stereotactic radiofrequency thermocoagulation.

Prognosis HDH usually has a poor prognosis and is lethal in about 50% of the cases. Mental retardation, epilepsy and precocious puberty are quite common complications (50-60%) in the surviving patients.

Cytogenetics

Note In one case a 7q36 terminal deletion was demonstrated, while another patient showed a 69, XXX triploid karyotype. Therefore, although rarely positive, standard karyotype and subtelomeric rearrangement analysis are recommended in all HDH patients.

Genes involved and Proteins

Gene Name SHH

Location 7q36

Note Although mutations of this gene have not yet been identified in HDH, a terminal 7q deletion has been documented in one patient and an additional case, showing single central medial incisive and hypophyseal hamartoma, has been described with SHH heterozygous mutation. These evidences suggest that SHH is a potential candidate-gene for those HDH cases who still lack a known cause (e.g. chromosome imbalance or teratogenic exposure).

Gene Name SOX2

Location 3q26.33

Note A single patient showing a SOX2 heterozygous mutation and presenting with hypothalamic hamartoma, unilateral microphthalmia, hypoplastic anterior hypophysis and corpus callosum has been described. Although the observed phenotype cannot be unambiguously interpreted as an atypical form of holoprosencephaly, future studies are expected to demonstrate a causal relationship between SOX2 mutations and HDH.

Bibliography

Gelastic seizure with tectal tumor, lobar holoprosencephaly, and subependymal nodules: clinical report.

Akman CI, Schubert R, Duran M, Loh J

Journal of child neurology. 2002 ; 17 (2) : 152-154.

PMID 11952080

Gelastic epilepsy, hypothalamic hamartoma, precocious puberty, and agenesis of the corpus callosum: a new association.

Alikchanov AA, Petrukhin AS, Mukhin KYu, Nikanorov AYu

Brain & development. 1998 ; 20 (4) : 239-241.

PMID 9661969

Hydrolethalus (Salonen-Herva-Norio) syndrome: further clinicopathological delineation.

Anyane-Yeboa K, Collins M, Kupsky W, Maidman J, Malin J, Yeh M

American journal of medical genetics. 1987 ; 26 (4) : 899-907.

PMID 3296755

Reassessment of holoprosencephaly-diencephalic hamartoblastoma (HDH) association.

Castori M, Douzgou S, Silvestri E, Encha-Razavi F, Dallapiccola B

American journal of medical genetics. Part A. 2007 ; 143 (3) : 277-284.

PMID 17230485

A triploid fetus further expands etiological heterogeneity in holoprosencephaly-diencephalic hamartoblastoma.

Castori M, Silvestri E, Nunnari J, Grammatico P, Dallapiccola B

American journal of medical genetics. Part A. 2007 ; 143 (12) : 1391-1393.

PMID 17497722

Congenital hypothalamic hamartoma syndrome: nosological discussion and minimum diagnostic criteria of a possibly familial form.

Encha-Razavi F, Larroche JC, Roume J, Migne G, Delezoide AL, Gonzales M, Mulliez N

American journal of medical genetics. 1992 ; 42 (1) : 44-50.

PMID 1308364

Meningeal angiomatosis, arhinencephaly, agenesis of the corpus callosum and large hamartoma of the brain, with neoplasia, in an infant having bilateral nasal proboscis.

GITLIN G, BEHAR AJ

Acta anatomica. 1960 ; 41 : 56-79.

PMID 13705778

Pallister-Hall syndrome associated with unbalanced chromosome translocation.

Golabi M, Kuller J, Cox K, KeilmanK, Schonberg S

Am J Med Genet. 1991 ; 49.

Hypothalamic hamartoma, gelastic epilepsy, precocious puberty--a diffuse cerebral dysgenesis.

Gulati S, Gera S, Menon PS, Kabra M, Kalra V

Brain & development. 2002 ; 24 (8) : 784-786.

PMID 12453604

Congenital hypothalamic hamartoblastoma, hypopituitarism, imperforate anus and postaxial polydactyly--a new syndrome? Part I: clinical, causal, and pathogenetic considerations.

Hall JG, Pallister PD, Clarren SK, Beckwith JB, Wiglesworth FW, Fraser FC, Cho S, Benke PJ, Reed SD

American journal of medical genetics. 1980 ; 7 (1) : 47-74.

PMID 7211952

Congenital hypothalamic hamartoma associated with severe midline defect: a developmental field defect. Report of a case.

Hennekam RC, Beemer FA, Van Merrienboer F, Van Ketel BA, Kramer PP

American journal of medical genetics. Supplement. 1986 ; 2 : 45-52.

PMID 3146299

Stereotactic radiofrequency thermocoagulation for hypothalamic hamartoma with intractable gelastic seizures.

Homma J, Kameyama S, Masuda H, Ueno T, Fujimoto A, Oishi M, Fukuda M

Epilepsy research. 2007 ; 76 (1) : 15-21.

PMID 17643965

Case report and delineation of the congenital hypothalamic hamartoblastoma syndrome (Pallister-Hall syndrome).

Iafolla K, Fratkin JD, Spiegel PK, Cohen MM Jr, Graham JM Jr

American journal of medical genetics. 1989 ; 33 (4) : 489-499.

PMID 2688416

Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans.

Kelberman D, Rizzoti K, Avilion A, Bitner-Glindzicz M, Cianfarani S, Collins J, Chong WK, Kirk JM, Achermann JC, Ross R, Carmignac D, Lovell-Badge R, Robinson IC, Dattani MT

The Journal of clinical investigation. 2006 ; 116 (9) : 2442-2455.

PMID 16932809

Hypothalamic hamartoma associated with a craniopharyngeal canal.

Kizilkilic O, Yalcin O, Yildirim T, Sener L, Parmaksiz G, Erdogan B

AJNR. American journal of neuroradiology. 2005 ; 26 (1) : 65-67.

PMID 15661703

Pallister-Hall syndrome associated with an unbalanced chromosome translocation.

Kuller JA, Cox VA, Schonberg SA, Golabi M

American journal of medical genetics. 1992 ; 43 (3) : 647-650.

PMID 1605268

Hamartoma of the hypothalamus; report of two cases with associated developmental defects.

MARCUSE PM, BURGER RA, SALMON GW

The Journal of pediatrics. 1953 ; 43 (3) : 301-308.

PMID 13085273

Bilateral nasal proboscis associated with unilateral anophthalmia, unilateral diffuse pigmentation of the conjunctiva, and anomalies of the skull and brain.

ROSEN Z, GITLIN G

A.M.A. archives of otolaryngology. 1959 ; 70 : 545-550.

PMID 14438899

Single median maxillary central incisor, hypophyseal tumor, and SHH mutation.

Ribeiro LA, Richieri-Costa A

American journal of medical genetics. Part A. 2005 ; 136 (4) : 346-347.

PMID 15942953

Diencephalic neuronal hamartoma associated with congenital obstructive hydrocephalus, anophthalmia, cleft lip and palate and severe mental retardation: a possible new syndrome.

Rossiter JP, Khalifa MM, Nag S

Acta neuropathologica. 2000 ; 99 (6) : 685-690.

PMID 10867803

Duplication of the pituitary gland as shown by MR.

Ryals BD, Brown DC, Levin SW

AJNR. American journal of neuroradiology. 1993 ; 14 (1) : 137-139.

PMID 8427075

Neonatal hypothalamic hamartoma: a differentiating nonlethal hamartoblastoma.

Saxonhouse MA, Yachnis AT, Burchfield DJ, Quisling R, Sullivan MP, Pincus DW

Journal of neurosurgery. 2005 ; 103 (3 Suppl) : 277-281.

PMID 16238084

Epignathus teratoma: report of three cases with a review of the literature.

Vandenhaute B, Leteurtre E, Lecomte-Houcke M, Pellerin P, Nuyts JP, Cuisset JM, Soto-Ares G

The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association. 2000 ; 37 (1) : 83-91.

PMID 10670895

Variability versus heterogeneity in syndromal hypothalamic hamartoblastoma and related disorders: review and delineation of the cerebro-acro-visceral early lethality (CAVE) multiplex syndrome.

Verloes A, Gillerot Y, Langhendries JP, Fryns JP, Koulischer L

American journal of medical genetics. 1992 ; 43 (4) : 669-677.

PMID 1621756

Syndromal hypothalamic hamartoblastoma with holoprosencephaly sequence, microphthalmia, pulmonary malformations, radial hypoplasia and müllerian regression: further delineation of a new syndrome?

Verloes A, Narcy F, Fallet-Bianco C

Clinical dysmorphology. 1995 ; 4 (1) : 33-37.

PMID 7735503

Solitary central maxillary incisor associated with precocious puberty and hypothalamic hamartoma.

Winter WE, Rosenbloom AL, Maclaren NK, Mickle JP

The Journal of pediatrics. 1982 ; 101 (6) : 965-967.

PMID 7143176

Citation

This paper should be referenced as such :

Castori, M ; Grammatico, P

Holoprosencephaly-diencephalic hamartoblastoma (HDH)

Atlas Genet Cytogenet Oncol Haematol. 2008;12(5):414-416.

Free journal version : [ pdf ] [ DOI ]

On line version : http://AtlasGeneticsOncology.org/Tumors/HoloDienHamartoID10142.html

REVIEW articles automatic search in PubMed

Last year articles automatic search in PubMed

Home Genes Leukemias Solid Tumors Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.

Other names	Holoprosencephaly-diencephalic hamartoblastoma association, Holoprosencephaly-hypothalamic hamartoblastoma, Holoprosencephaly-diencephalic hamartoma
Atlas_Id	10142
Genes implicated in	SHH SOX2
Note	HDH is an extremely rare developmental field defect primarily involving the prosencephalon. The most accredited hypothesis is that the hypothalamic hamartoma formation, which occurs early in embryogenesis, produces a cascading process of subsequent craniofacial defects including holoprosencephaly, microphthalmia, hemifacial microsomia, neuronal migration defects, and brainstem/posterior fossa and meningeal anomalies.
Inheritance	The inheritance pattern of HDH is still obscure and probably heterogeneous. Environmental/stochastic causes may also contribute for a significant proportion of cases.

Phenotype and clinics	HDH equally affects males and females. Nearly 100% of the patients present some features of holoprosencephaly. The spectrum of these anomalies is wide, ranging from alobar holoprosencephaly to microforms, such as isolated single central medial incisive, or cleft palate. The most consistent holoprosencephalic features are hypo/aplasia of the corpus callosum, arhinencephaly and premaxillary agenesis. Unilateral or bilateral microphathalmia and neuronal migration/cortical anomalies are quite common abnormalities. Additional findings include meningeal abnormalities, such as cysts and dysplasia, and brainstem and posterior fossa malformations. The first and second branchial arches derivatives may also be asymmetrically affected leading to a significant clinical overlap with the oculo-auriculo-vertebral spectrum. Fifty to sixty per cent of the patients also show extracephalic features, with an excess of midline and laterality determination abnormalities, thus configuring a polytopic developmental field defect. The axial skeleton is the most commonly involved structure, while heart, kidneys, gastrointestinal tract, genitourinary system and limbs are more rarely affected.
Neoplastic risk	On embryological perspective, hypothalamic hamartoma/hamartoblastoma is a malformation, not a true tumor. Other benign growth lesions, including meningeal angiomatosis, frontal lipoma, tongue cyst, epignathus and gum nodules, have been observed in about 20% of the cases. However, no increased risk of malignancies has been reported in HDH patients.
Treatment	In those patients who survive (see below), the treatment is usually conservative and symptomatic. Surgical repair could be requested for specific potentially life-treating or disfiguring malformations, such as cleft palate, congenital heart disease and genital anomalies. Invasive treatment of hypothalamic hamartomas is usually requested only in presence of intractable seizures. In this case, the experience is limited to non syndromic hamartomas and therapeutic options include surgical resection by conventional craniotomy, microsurgical technique via transcallosal approach and stereotactic radiofrequency thermocoagulation.
Prognosis	HDH usually has a poor prognosis and is lethal in about 50% of the cases. Mental retardation, epilepsy and precocious puberty are quite common complications (50-60%) in the surviving patients.

Gene Name	SHH
Location	7q36
Note	Although mutations of this gene have not yet been identified in HDH, a terminal 7q deletion has been documented in one patient and an additional case, showing single central medial incisive and hypophyseal hamartoma, has been described with SHH heterozygous mutation. These evidences suggest that SHH is a potential candidate-gene for those HDH cases who still lack a known cause (e.g. chromosome imbalance or teratogenic exposure).

Gene Name	SOX2
Location	3q26.33
Note	A single patient showing a SOX2 heterozygous mutation and presenting with hypothalamic hamartoma, unilateral microphthalmia, hypoplastic anterior hypophysis and corpus callosum has been described. Although the observed phenotype cannot be unambiguously interpreted as an atypical form of holoprosencephaly, future studies are expected to demonstrate a causal relationship between SOX2 mutations and HDH.

REVIEW articles	automatic search in PubMed
Last year articles	automatic search in PubMed